Sentences with phrase «placebo groups at»

Migraine days were significantly reduced within all three groups from baseline to post-treatment; the effect continued in the CSMT and placebo groups at all follow - up time points, whereas the control group returned to baseline.

The results show that the probiotic group fussed significantly more than the placebo group at all time points from day seven to one month.

The average spine BMD also increased more in the treatment group than placebo group at 12 months (3 percent vs. 1.1 percent) and at 24 months (4.5 percent vs. 0.7 percent).

Resolved enthesitis occurred in 29.0 % of those patients with enthesitis at baseline in the placebo group at week 24, versus 56.6 % on guselkumab (p = 0.012).

Acne showed improvement in the lactoferrin group by significant decreases in inflammatory lesion count by 38.6 %, total lesion count by 23.1 %, and acne grade by 20.3 % compared with the placebo group at 12 wk.

Not exact matches

The double - blind, placebo - controlled study, conducted by Glyn Howatson and Phillip G. Bell at Northumbria University in the UK, involved 16 well - trained male cyclists who were divided into two groups: one consuming Montmorency tart cherry juice and the other a placebo beverage including an equal amount of carbohydrates.

At the end of the study, the curcumin group had lower levels of three blood markers of inflammation, including C - reactive protein (CRP), along with lower fasting blood sugar and hemoglobin A1c (a measure of longer term blood sugar levels).5 For comparison, the placebo group had higher blood sugar levels and increased inflammation after the eight weeks.

Although none of the groups reported on drug side effects, while Guo who tested only breastfed infants reported on significant decrease in infant crying, and decrease in depressive symptoms at one month and at two months respectively, Sung who tested both formula fed and breastfed infants reported on increase crying in the probiotic treated infants (particularly in the formula fed infants) compared to placebo with no effect on maternal depressive symptoms.

Meta - analysis revealed no significant differences between LCPUFA and placebo groups in BSID Mental Developmental Index (MDI) scores at 18 months (MD 0.06, 95 % CI -2.01 to 2.14; I2 = 75 %; four trials; N = 661) and no significant differences in BSID Psychomotor Development Index (PDI) scores at 18 months (MD 0.69, 95 % CI -0.78 to 2.16; I2 = 61 %; four trials; N = 661).

At one month, the probiotic group cried or fussed 49 minutes more than the placebo group.

The researchers found the children whose mothers took the DHA supplement during pregnancy had an average of 1.3 pounds more fat - free mass but the same amount of fat at age 5 compared with the placebo group.

At baseline, study patients had an average Clinician - Administered PTSD Scale (CAPS) score of 79, but after MDMA - assisted therapy, CAPS scores dropped to 23.4 in the 13 - person MDMA group, whereas an eight - person placebo group averaged a score of 60.

Patients were randomised into eight treatment groups: a single dose regimen of 200, 300 or 500 mg inclisiran, or placebo; or a two dose regimen of 100, 200 or 300 mg inclisiran, or placebo, at days one and 90.

Among subjects who had prediabetes at the beginning of the study (arm 2), blood sugar levels reverted to normal in nearly 70 percent of those receiving liraglutide versus 32 percent of people in the placebo group, according to the abstract.

The study assigned 249 healthy, previously sedentary women at multiple sites, including Group Health, to do yoga, a moderate aerobic exercise program, or neither — and to take an omega - 3 fatty acid supplement or a placebo.

At the end of the study, there was no difference between the cinnamon and placebo groups in terms of glucose or cholesterol.

Only in patients with moderate or severe knee pain at the outset did the supplements show a significant advantage over the placebo, with almost 80 percent of that group reporting a significant improvement, compared with 54.3 percent who took the inert pills.

At 600 IUs, arterial stiffness actually increased slightly — .1 percent — and the placebo group experienced a 2.3 percent increase in arterial stiffness over the timeframe.

The primary endpoint of death and non-fatal heart attack at 30 days was no different between the two groups (7 percent in the aspirin group and 7.1 percent in the placebo group); however, major bleeding was significantly higher in aspirin - treated patients than in the placebo group (4.6 percent vs. 3.7 percent).

At one point volunteer canvassers who were not identified as affiliated with the surveys went door - to - door for a conversation with participants; some talked about transgender issues, the «placebo» group talked about recycling.

At a median follow - up of 2.74 years, the median recurrence - free survival was 26.1 months (95 % confidence interval (CI) 19.3 — 39.3) in the Ipilimumab group and 17.1 months (95 % CI 13.4 — 21.6) in the placebo group (hazard ratio 0.75; 95 % CI 0.64 — 0.90; p = 0.0013).

Patients with IBS, based on Rome III criteria, were assigned randomly to groups given pinaverium or placebo at four hospitals in China, from August 2012 through December 2013.

The therapy had a favorable safety profile with the most common adverse event reported as irritation at injection site, which was reported in the placebo group as well.

Using this measure, the researchers saw that 37.6 percent of patients on the monthly regimen, and 40.8 percent on the quarterly regimen had at least a 50 percent reduction in the number of moderate headaches per month, compared to 18.1 percent in the placebo group.

In all, they analyzed 35 trials, each of which involved a group of patients who took a placebo and at least one group who took one of those four antidepressants.

Angiotensin II significantly improved hypotension (low blood pressure)-- increasing mean arterial pressure at 3 hours — compared with placebo; nearly 70 percent of angiotensin II - treated patients (114 of 163) saw improved blood pressure compared with 23 percent of the placebo group (37 of 158 patients).

In order to examine the «placebo breaking the blind» theory, a research group at the Sahlgrenska Academy in Gothenburg, Sweden, has now analyzed data from the clinical trials that were once undertaken to establish the antidepressant efficacy of two of the most commonly used SSRIs, paroxetine and citalopram.

Looking at the components of the primary outcome separately, only hospitalizations, specifically for heart failure, had a significantly lower incidence for those taking spironolactone compared to placebo, with 206 patients (12.0 percent) in the spironolactone group undergoing hospitalization versus 245 patients (14.2 percent) in the placebo group.

Both groups of participants assigned at random to varenicline achieved significantly higher abstinence rates at 12 weeks than those assigned to placebo, nicotine patch or bupropion.

The experiment was divided into two phases: Phase 1 (30 stimuli; duration 5 min) was followed by a submucosal injection of the anaesthetic articaine 4 % (group A) or 0.9 % NaCl as placebo (group P) at the left mental foramen.

At week 4, 47.1 percent of participants treated with varenicline reduced the number of cigarettes smoked per day compared with baseline by 50 percent or more or abstained completely compared with 31.1 percent of participants treated with placebo; after 8 weeks, 26.3 percent participants in the varenicline group reduced smoking by 75 percent or more from baseline or abstained compared with 15.1 percent participants in the placebo group.

The researchers found that the addition of vitamin D3 to ciclesonide did not significantly reduce the rate of first treatment failure (a composite outcome of decline in lung function and increases in use of beta - agonists, systemic steroids, and health care utilization) compared with placebo; 28 percent and 29 percent of participants in each group, respectively, experienced at least 1 treatment failure during 28 weeks.

The trial in Sierra Leone would not use a placebo but instead would offer groups of health care workers the vaccine at different points in time.

So, we added a placebo for the «Basic group» and added risperidone for the «Augmented group,» if there was room for improvement at the end of the third week,» said Aman, also coordinating principal investigator of the multi-site study.

At the one - year mark, the ADRC treated patients with at least one class improvement in heart failure class (57 percent) and angina class (67 percent) tended to be higher relative to the placebo group (15 percent and 27 percent, respectivelyAt the one - year mark, the ADRC treated patients with at least one class improvement in heart failure class (57 percent) and angina class (67 percent) tended to be higher relative to the placebo group (15 percent and 27 percent, respectivelyat least one class improvement in heart failure class (57 percent) and angina class (67 percent) tended to be higher relative to the placebo group (15 percent and 27 percent, respectively).

Nearly 40 % of patients in the active group, vs. 6.3 % in the placebo arm, achieved PASI 100 (completely clear skin) at week 24.

In order to examine the «placebo breaking the blind» theory, a research group at the Sahlgrenska Academy, has now analyzed data from the clinical trials that were once undertaken to establish the antidepressant efficacy of two of the most commonly used SSRIs, paroxetine and citalopram.

And the percentage of patients achieving minimal disease activity at week 24 was 2 % for placebo compared to 23 % in the guselkumab group (p = 0.001).

Looked at another way, 95 percent of the women in the letrozole group experienced disease - free survival for five years, compared with 91 percent in the placebo group.

There were no substantive differences between study groups at baseline; 8506 women were randomized into the estrogen plus progestin group and 8102 into the placebo group (Table 1a).

In March 2008, a 15,000 - person study comparing Crestor (rosuvastatin) against placebo in two groups of outwardly healthy people with low levels of LDL cholesterol and high levels of CRP was stopped early — a «stunning» outcome, the lead researcher said at the time — because the reduction in cardiac events was so marked among the participants taking the drug that to continue the trial and deprive the placebo group of the drugs benefits would have been unethical.

At this point, the placebo group was dismissed from the study and the Obalon group had their balloons removed.

At the beginning of the study, the average severity of the men's symptoms measured about 14.5 on a 35 - point scale commonly used by urologists; by the end, the average severity had declined by three points in the placebo group and just two points in the saw palmetto group.

The study looked at the effect of dietary supplementation using 2,000 international units of nonprescription vitamin E daily in a large group of elderly Alzheimer's patients and compared their results over an average of around two years to similar patients who received a placebo, a pharmaceutical marketed as a «treatment» for Alzheimer's disease (memantine), or a combination of memantine along with vitamin E.

Another study which wanted to eliminate this particular limitation examined the impact that 8 grams of creatine had on muscle size and strength taken immediately after or before workout sessions, while at the same time adding a control group which took a placebo lacking creatine.

Even though both of the aforementioned studies pose a strong indication that creatine dose timing is important, neither one of them had a control group that participated in lifting weights while at the same time taking a placebo dose which logically did not have creatine monohydrate.

At the same time, the women in the placebo group actually gained body fat.

At two months, the silymarin group experienced an 86 percent increase, compared to 32 percent in the placebo group.

The company recently announced that in one trial of 505 obese people with type 2 diabetes, 45 % of patients taking Contrave32 lost at least 5 % of their body weight compared to patients in a placebo group; only 19 % of the placebo group lost at least 5 % of their body weight.

After three months, the LDL levels of those taking the active red yeast rice had declined 27 %, on average, compared to 6 % in the placebo group; at six months the decline in the active group was still more than 21 %.